Adagio Therapeutics Inc. [ADGI] moved up 30.39: Why It’s Important


Adagio Therapeutics Inc. [NASDAQ: ADGI] closed the trading session at $5.02 on 03/30/22. The day’s price range saw the stock hit a low of $5.00, while the highest price level was $6.14. The company report on March 30, 2022 that Adagio Therapeutics Announces ADG20 (adintrevimab) is the First Monoclonal Antibody to Meet Primary Endpoints with Statistical Significance Across Pre- and Post-exposure Prophylaxis and Treatment for COVID-19 and Plans to Seek U.S. Emergency Use Authorization.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Risk of symptomatic COVID-19 was reduced by 71% compared to placebo in pre-exposure prophylaxis and 75% compared to placebo in post-exposure prophylaxis.

Risk of hospitalization or death in participants with mild to moderate COVID-19 was reduced by 66% compared to placebo in the primary efficacy analysis population and by 77% compared to placebo in participants who received treatment within three days of symptom onset.

The stocks have a year to date performance of -30.85 percent and weekly performance of 20.10 percent. The stock has been moved at -87.62 percent over the last six months. The stock has performed -23.01 percent around the most recent 30 days and changed -33.69 percent over the most recent 3-months.

If compared to the average trading volume of 3.07M shares, ADGI reached to a volume of 91845485 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Adagio Therapeutics Inc. [ADGI]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ADGI shares is $8.33 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ADGI stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Morgan Stanley have made an estimate for Adagio Therapeutics Inc. shares, keeping their opinion on the stock as Underweight, with their previous recommendation back on January 06, 2022. While these analysts kept the previous recommendation, Jefferies dropped their target price from $46 to $10. The new note on the price target was released on December 22, 2021, representing the official price target for Adagio Therapeutics Inc. stock. Previously, the target price had yet another drop from $50 to $9, while Stifel kept a Hold rating on ADGI stock.

The Average True Range (ATR) for Adagio Therapeutics Inc. is set at 0.58 The Price to Book ratio for the last quarter was 0.49, with the Price to Cash per share for the same quarter was set at 5.65.

ADGI stock trade performance evaluation

Adagio Therapeutics Inc. [ADGI] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 20.10. With this latest performance, ADGI shares dropped by -23.01% in over the last four-week period, additionally sinking by -87.62% over the last 6 months .

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ADGI stock in for the last two-week period is set at 47.73, with the RSI for the last a single of trading hit 56.61, and the three-weeks RSI is set at 43.55 for Adagio Therapeutics Inc. [ADGI]. The present Moving Average for the last 50 days of trading for this stock 6.14, while it was recorded at 4.17 for the last single week of trading.

Adagio Therapeutics Inc. [ADGI]: An insightful look at the core fundamentals

Reflecting on the efficiency of the workforce at the company, Adagio Therapeutics Inc. [ADGI] managed to generate an average of -$1,333,041 per employee.Adagio Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 12.80 and a Current Ratio set at 12.80.

Adagio Therapeutics Inc. [ADGI]: Insider Ownership positions

There are presently around $209 million, or 66.90% of ADGI stock, in the hands of institutional investors. The top three institutional holders of ADGI stocks are: FMR LLC with ownership of 15,592,582, which is approximately -6.563% of the company’s market cap and around 53.50% of the total institutional ownership; M28 CAPITAL MANAGEMENT LP, holding 5,665,221 shares of the stock with an approximate value of $21.81 million in ADGI stocks shares; and RA CAPITAL MANAGEMENT, L.P., currently with $19.23 million in ADGI stock with ownership of nearly -6.448% of the company’s market capitalization.

Positions in Adagio Therapeutics Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 55 institutional holders increased their position in Adagio Therapeutics Inc. [NASDAQ:ADGI] by around 14,598,933 shares. Additionally, 37 investors decreased positions by around 6,710,470 shares, while 7 investors held positions by with 33,049,707 shares. The mentioned changes placed institutional holdings at 54,359,110 shares, according to the latest SEC report filing. ADGI stock had 36 new institutional investments in for a total of 11,848,835 shares, while 20 institutional investors sold positions of 744,729 shares during the same period.